Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-04 22:01:33 - browse：824

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — The booming obesity market is attracting another player, as pharma giant Roche said Monday it was acquiring Carmot Therapeutics and the company’s line of weight loss drug candidates for $2.7 billion upfront.

The deal for Carmot, which is based in Berkeley, Calif., includes additional milestone payments of up to $400 million. Carmot is privately held, though it had filed paperwork last month for an initial public offering.

As part of the deal, Roche is gaining three experimental obesity medicines from Carmot, which are in Phase 1 or Phase 2 testing, as well as preclinical programs. While two are injectable treatments, one is being developed as an oral drug. They all target GLP-1 hormone receptors, while two are also designed to work via receptors for another hormone called GIP.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： STAT letters to the editor on burnt

entertainment

WSS

CMS should re

CMS should re

Leukemia patients are helped by Syndax's new type of therapy

STAT letters to the editor on burnt

Medicare will require more price transparency from hospitals

The Sacklers, horror, and ‘The Fall of the House of Usher’

focus

Wikipedia

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The Sacklers, horror, and ‘The Fall of the House of Usher’

In Memoriam: Notable people who died in 2023

The woman behind the Dana Farber

Moonlake's readout produced a cash windfall. Risks remain

Removing probiotics from the NICU could threaten preemies' health

Medicare proposal to cover medical devices draws a mixed reaction

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Hollywood unions extend contract negotiations for actors

Leukemia patients are helped by Syndax's new type of therapy

focus

SCOTUS to consider access to abortion pill mifepristone

FDA approves Recor Medical high blood pressure device

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

STAT letters to the editor on burnt

FDA approves potent Eli Lilly obesity drug, Zepbound

Removing probiotics from the NICU could threaten preemies' health

focus

knowledge

entertainment

focus